IS 001
Alternative Names: IS-001Latest Information Update: 11 Sep 2023
At a glance
- Originator ImmuSmol
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Sep 2023 Preclinical development is ongoing in Cancer in France (Parenteral) (ImmuSmol website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 21 Jul 2016 IS 001 is available for licensing as of 21 Jul 2016. https://www.immusmol.com